reference/28306522

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/28306522

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Clinical Trial, Phase II\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	176
issn	1552-4949 1552-4957
issueIdentifier	2
pageRange	168-176
publicationName	Cytometry. Part B, Clinical cytometry
startingPage	168
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_9ad628b6af1c1185430549d35f513d98 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_96a6fc76e52b8283e4887f6b7ec6f603 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_70ea0d2cc2361e2884a25a9cb76ab6d6
bibliographicCitation	Wyant T, Estevam J, Yang L, Rosario M. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab. Cytometry B Clin Cytom. 2016 Mar;90(2):168–76. doi: 10.1002/cyto.b.21236. PMID: 25908521.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_17345f915aa26e8d4afaae0b1c1f5f46 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c2589d5de20e3b93859dc9ef3e570d70 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8ebaad1603e10782d379fc1bbde00a8b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c4069c09656cd629bfa1528ccd118c80
date	2015-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/25908521 https://doi.org/10.1002/cyto.b.21236
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/32206 https://portal.issn.org/resource/ISSN/1552-4949 https://portal.issn.org/resource/ISSN/1552-4957
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab
discusses	http://id.nlm.nih.gov/mesh/M0194830 http://id.nlm.nih.gov/mesh/M0462870 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0370990 http://id.nlm.nih.gov/mesh/M0539116 http://id.nlm.nih.gov/mesh/M0011122 http://id.nlm.nih.gov/mesh/M0460355 http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0024220 http://id.nlm.nih.gov/mesh/M0023752 http://id.nlm.nih.gov/mesh/M0429950 http://id.nlm.nih.gov/mesh/M0014177 http://id.nlm.nih.gov/mesh/M0024497
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D047988Q000302 http://id.nlm.nih.gov/mesh/D005434 http://id.nlm.nih.gov/mesh/D009088Q000302 http://id.nlm.nih.gov/mesh/D003093Q000188 http://id.nlm.nih.gov/mesh/D007136Q000302
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D002448Q000276 http://id.nlm.nih.gov/mesh/D009088Q000097 http://id.nlm.nih.gov/mesh/D061067Q000276 http://id.nlm.nih.gov/mesh/D047988Q000097 http://id.nlm.nih.gov/mesh/D000911Q000008 http://id.nlm.nih.gov/mesh/D047988Q000276 http://id.nlm.nih.gov/mesh/D016023Q000276 http://id.nlm.nih.gov/mesh/D010361 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D009088Q000276 http://id.nlm.nih.gov/mesh/D048868 http://id.nlm.nih.gov/mesh/D007136Q000097 http://id.nlm.nih.gov/mesh/D003093Q000097 http://id.nlm.nih.gov/mesh/D007136Q000276 http://id.nlm.nih.gov/mesh/D003093Q000276 http://id.nlm.nih.gov/mesh/D000911Q000276 http://id.nlm.nih.gov/mesh/D015415Q000097 http://id.nlm.nih.gov/mesh/D015815 http://id.nlm.nih.gov/mesh/D008214Q000276 http://id.nlm.nih.gov/mesh/D061067Q000008 http://id.nlm.nih.gov/mesh/D016023Q000378
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7300 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_73ec1fd1e62ddf66ee9632d3dddd18cf http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7365

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID8174 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID10758

Total number of triples: 70.